Increases in non-healthy behaviors such as drinking and less exercise has been attributed to the COVID-19 pandemic. The incidence was seen with the use of 18F-fluorocholine PET/CT and 68Ga-PSMA-11 PET/CT. The study is the first to show that lingering COVID-19 symptoms can be attributed to ongoing lung inflammation. This study offers a realist approach to rethinking and operationalizing the WHO 2017 guide to cancer early diagnosis. Researchers examined the association between the pandemic and prostate biopsy and cancer diagnosis. An overview of the effects of the COVID-19 pandemic on patient care and its effects on oncology care and medical education. The COVID-19 pandemic has brought about unprecedented changes in urologic care. A scientific session from the SNMMI Annual Meeting details how imaging can assess the impact of COVID-19 in cancer patients. The COVID-19 outbreak impacted patients with prostate cancer by causing a delay in the administration treatment. Patients with COVID-19 reported increased genitourinary symptoms. Previous Bacillus Calmette-Guérin therapy impacts COVID risk in bladder cancer. A study evaluated trends in outpatient prostate cancer throughout the COVID-19 pandemic using a community-based registry. Jeremy Warner summarizes the paper published in Lancet describing the outcome of cancer patients with COVID-19.